Sanaria’s malaria vaccine shows promise
August 9, 2013Research and Development, Sales and Marketing PfSPZ, Vaccine, malaria, sanaria
Researchers in the US have announced promising results from a Phase I clinical trial of biotech firm Sanaria’s new malaria …
AllTrials campaign releases manifesto
August 9, 2013Medical Communications, Research and Development, Sales and Marketing Bad pharma, GSK, Goldacre, NICE, transparency
The UK clinical trial transparency initiative AllTrials has released its first detailed manifesto as it looks to ramp up pressure …
Ranbaxy taps into Malaysian growth with second facility
August 9, 2013Manufacturing and Production ASEAN, Ranbaxy, asian, malaysian
Indian drugmaker Ranbaxy has signed a deal to construct a new $35 million manufacturing facility in Malaysia that will triple …
GSK banks on bioelectronics with new fund
August 9, 2013Medical Communications, Research and Development, Sales and Marketing Bioelectronics, COPD, GSK, asthma, diabetes
GSK has established a $50 million venture capital fund to invest in the emerging field of bioelectronics. Described as one …
BMJ appoints US managing director
August 9, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMJ, Campbell
Medical journal BMJ has hired Glen Campbell from Elsevier to be its US managing director. Campbell joins BMJ on 2 …
GSK seeks licence extensions
August 8, 2013Sales and Marketing Cervarix, EMA, GSK, Votrient
GlaxoSmithKline is seeking to extend the licences of two of its brands, Cervarix and Votrient, in a bid to extend …
Novartis recognised for efforts in cancer
August 8, 2013Medical Communications, Sales and Marketing Bush, CEO, Cancer, Novartis
Novartis is the first company to earn a global CEO Cancer Gold Standard accreditation by the non-profit organisation CEO Roundtable …
Late-stage failure for Afinitor
August 8, 2013Research and Development, Sales and Marketing Afinitor, Cancer, Novartis, liver
Novartis’ oncology programme has received a blow with the news that Afinitor has failed to help patients live longer in …
New junior planner at PAN
August 8, 2013Medical Communications, Sales and Marketing Pan, comms, doshi
Parrus Doshi has joined creative comms agency PAN from Langland Advertising as junior planner. Doshi was an account manager at …
Merck to shut New Jersey campus, shedding 113 jobs
August 8, 2013Manufacturing and Production Jobs, Merck, Schering-Plough, cuts
Merck & Co has followed through with an earlier threat to close down its manufacturing operations at Kenilworth, New Jersey. …
Merck KGaA declines in Q2
August 7, 2013Sales and Marketing Erbitux, Merck KGaA, Q2, Serono
Sales of cancer drug Erbitux dropped as Merck Serono’s revenues for the second quarter of 2013 dipped year-on-year, the firm …
Report: ‘Improve NHS safety’
August 7, 2013Sales and Marketing Cameron, Hunt, Mid Staffs, NHS
Patient safety is the key to future NHS success, according to a new review commissioned after the final report of …
Eylea trial boost in DME
August 7, 2013Research and Development, Sales and Marketing Bayer, DME, Eylea, regenenron
The rival treatment to Novartis’ Lucentis has posted encouraging new study results in patients with diabetic macular oedema (DME). In …
ICH starts consultation on elemental impurities guidance
August 7, 2013Manufacturing and Production ICH, Q3D, Taylor, USP
The International Conference on Harmonization (ICH) has started the consultation period on its long-awaited guidance on elemental impurities, a couple …
Waggener Edstrom expands UK healthcare team
August 7, 2013Medical Communications, Research and Development, Sales and Marketing Waggener Edstrom, foster
Comms agency Waggener Edstrom Worldwide (WE) has appointed Matt Foster to its healthcare practice as an account director. Foster will …
FDA makes GSK wait
August 6, 2013Sales and Marketing FDA, GSK, albiglutide, diabetes
The FDA is making GlaxoSmithKline wait for a verdict on the manufacturer’s investigational type 2 diabetes treatment albiglutide, extending its …
GSK loses Tyverb patent
August 6, 2013Sales and Marketing Cancer, GSK, GlaxoSmithKline, Tyverb
GlaxoSmithKline has received a knockback from authorities in India, who have revoked the patent on its breast cancer drug Tyverb. …
Roche breast cancer drug Perjeta rejected by NICE
August 6, 2013Sales and Marketing Cancer, NICE, Perjeta, Roche
NICE is not recommending Roche’s next generation breast cancer drug Perjeta as a treatment for a particular type of advanced …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
